Biest cream and the estradiol patch are both transdermal estrogen therapies for menopause symptoms, but they differ in one decisive way: the estradiol patch is an FDA-approved product that delivers a standardized, measured dose, while compounded biest cream is not FDA-approved and adds a second estrogen (estriol) in a customizable, less precisely measured cream.

Key takeaways

  • Both are applied to the skin, so both skip the liver "first pass" that makes oral estrogen riskier for blood clots.
  • The estradiol patch is FDA-approved and delivers a known amount of estradiol (0.025 to 0.1 mg per day). Compounded biest cream is not FDA-approved and its absorbed dose is less precisely characterized.
  • The patch is estradiol only. Biest adds estriol (a weaker estrogen), which is the main reason some women and clinicians prefer it.
  • The best head-to-head pharmacokinetic data (Sood 2013) found compounded creams often deliver less estradiol than a patch, so there is no clean "this much cream equals this patch" conversion.
  • Both carry the real risks of estrogen therapy: blood clots, stroke, breast cancer. A physician should review your history before either is prescribed.

If you are weighing a compounded biest cream against an FDA-approved estradiol patch, the useful question is not "which is better" in the abstract. It is "what does each one actually give up, and which trade fits you." This page goes deeper than the biest cream overview on exactly that comparison. Therisse is a physician-led practice, so the goal here is an accurate trade-off, not a sales pitch for one option.

Biest cream vs estradiol patch at a glance

Estradiol patch Biest cream
FDA status FDA-approved Not FDA-approved (compounded)
Estrogens Estradiol only Estriol + estradiol (two)
Dose Standardized, measured (0.025 to 0.1 mg/day) Customizable, less precisely measured
How it is used Adhesive patch, changed once or twice weekly Cream applied to skin, usually once daily
Route Transdermal (skips liver first pass) Transdermal (skips liver first pass)
Dosing data Well studied and consistent Limited; tends to under-deliver at lower strengths
Customization Fixed dose steps Ratio and strength can be tailored

Is the estradiol patch better than biest cream?

For predictability, yes. The estradiol patch is FDA-approved, which means it went through premarket testing for safety, efficacy, and consistent dosing. When you apply a 0.05 mg/day patch, the amount of estradiol reaching your blood is known and reproducible. That is a real advantage, and it is why the American College of Obstetricians and Gynecologists (ACOG), The Menopause Society, and the National Academies recommend FDA-approved hormone therapy over compounded options when an FDA-approved option exists.

"Better" is not only about predictability, though. The patch is estradiol only. Biest cream adds estriol, the weaker estrogen, which is the reason some women choose it, and it lets a physician tailor the ratio and strength rather than picking from fixed patch steps. The honest framing: the patch wins on standardization and evidence; biest offers a second estrogen and customization, at the cost of less precise dosing.

Estradiol patch vs cream: is there an equivalent dose?

This is the most searched and most over-promised part of the comparison, so here is the careful answer: there is no validated one-to-one conversion between a biest cream and an estradiol patch.

The single randomized pharmacokinetic trial most often cited (Sood and colleagues, Maturitas, 2013, a 40-woman study) compared compounded biest creams to a standard estradiol patch. It found the creams generally delivered less estradiol into the bloodstream than the patch, with one exception: at the highest cream strength tested (3.0 mg), blood levels were not statistically different from the patch. Lower-strength creams tended to under-deliver.

What that means in practice:

  • "Amount of cream applied" does not map cleanly onto "amount of estradiol absorbed" in the published literature.
  • Anyone who hands you an exact patch-equivalent for a biest cream is overstating what is actually known.
  • It is also why a reputable practice starts biest at a conservative strength and titrates upward based on your response, rather than assuming a starting dose is "enough." (Therisse's standard starter is biest 80/20 at 2.5 mg/gm. More on ratios and strength in the biest cream overview.)

Estriol, the second estrogen in biest, adds another reason the comparison is not clean: the patch contains none of it, so the two products are not delivering the same hormones in the first place.

Side effects: estradiol patch vs cream

The side-effect profiles are similar because both are estrogen therapy delivered through the skin. The common ones for either:

  • Breast tenderness or swelling
  • Spotting or breakthrough bleeding
  • Headache or nausea
  • Bloating or fluid retention

The differences are mostly about delivery, not the hormone:

  • Skin reactions differ by format. Patches can cause adhesive irritation or redness where they stick, and can loosen with heat or sweat. Creams can irritate at the application site and carry a small risk of transferring estrogen to others (a partner or child) through skin contact if the area is not covered or washed.
  • Consistency differs. A patch holds a steadier level between changes. A daily cream depends on consistent application and absorption, which can vary with the site and the skin.

On weight specifically: there is no good evidence that either biest cream or an estradiol patch reliably causes weight gain. Body-composition changes around menopause are common on their own.

Blood clot risk: an important point both share

Route matters for clot risk, and this is where the two products are actually alike. Large observational research (the ESTHER study) found that oral estrogen raised the risk of venous blood clots while transdermal (through-the-skin) estrogen did not show the same increase, likely because skin-applied estrogen skips the liver "first pass" that drives clotting factors.

Both the patch and biest cream are transdermal, so both share that more favorable route compared with estrogen pills. This is reassuring context, not a guarantee: estrogen therapy still carries established risks of blood clots, stroke, and breast cancer, and the compounded-cream evidence base specifically is thinner than the patch's. A physician reviews your history (including any personal or family history of clots, stroke, or hormone-sensitive cancers) before prescribing either one.

Which should you choose?

There is no universal answer, but the trade-off sorts cleanly:

  • Lean toward the estradiol patch if your priority is well-studied, predictable dosing with the most evidence behind it, and you do not need the estriol component.
  • Lean toward biest cream if you specifically want the estriol component or a customizable ratio and strength, and you accept that delivery is less precisely characterized. (For women who still have a uterus, either estrogen is paired with progesterone to protect the uterine lining.)

The decision belongs with a clinician who has seen your history, not a website. What a physician-led practice can do is be honest about which box you are actually choosing.

How Therisse handles this

Therisse prescribes compounded biest cream, dispensed by a licensed 503A compounding pharmacy, after a board-certified physician reviews your intake and history. We start at a conservative, defensible strength (biest 80/20 2.5 mg/gm) and adjust based on how you respond. If a physician judges that an FDA-approved option like a patch is the better fit for you, that is a conversation to have with them, not something a form should override.

Prescription products require an online consultation with a licensed provider. If a physician does not approve you, your initial consult fee and any medication charge are refunded in full.

Compounded products are not FDA-approved. This page is educational and is not medical advice. Hormone therapy is not right for everyone, and it carries risks including blood clots, stroke, and breast cancer. Talk to a licensed clinician about your individual history.

Frequently asked questions

Is biest cream the same as the estradiol patch? No. The patch is FDA-approved and delivers estradiol only in a standardized dose. Biest cream is compounded (not FDA-approved) and contains two estrogens, estriol and estradiol, in a customizable cream.

Is the estradiol patch better than biest cream? The patch has more evidence and more predictable dosing, and major medical bodies prefer FDA-approved options. Biest offers a second estrogen (estriol) and customization, with less precise dosing. The right choice depends on your history and priorities.

What is the estradiol patch equivalent of biest cream? There is no validated one-to-one conversion. The main trial (Sood 2013) found compounded creams often delivered less estradiol than a patch, so an exact equivalent cannot be stated honestly.

Do biest cream and the estradiol patch have the same clot risk? Both are transdermal, so both skip the liver first pass linked to higher clot risk with oral estrogen. Estrogen therapy still carries real risks (blood clots, stroke, breast cancer), and the compounded-cream evidence base is more limited.

Is biest cream FDA approved? No. Compounded biest cream is not FDA-approved. Certain estradiol patches, pills, and gels are FDA-approved; compounded biest is made for an individual patient and not reviewed as a standardized product.

Sources